Jupiter Endovascular
Carl St. Bernard currently serves as the Chief Executive Officer of Jupiter Endovascular since July 2024. In addition, Carl holds board member positions at Transverse Medical Inc and AdvaMed, both established in March 2021, and served as President and CEO of ALTA Biomaterials from January 2023 to June 2024. Previously, Carl was President & CEO of CeloNova BioSciences, Inc. from August 2019 to January 2023, and President & CEO of Tryton from December 2017 to June 2019. Carl has also held various leadership roles at Johnson & Johnson Vision Care, Inc., LifeCell Corporation, and DePuy Synthes Companies of Johnson & Johnson. Academic qualifications include an MBA in Business from Pepperdine Graziadio Business School and an Executive Leadership Program from Northwestern University - Kellogg School of Management, along with a B.A. in Economics and Business from Lafayette College.
This person is not in any teams
Jupiter Endovascular
Imagine a world where you could bring the precision and control of surgery to catheter-based therapies. For decades, endovascular procedures have been constrained by the technological limitations of catheters that lose stability and control within the anatomy. We have created a new class of therapies to overcome these constraints by using Endoportal Control to mimic the precision and control of direct surgical access, while maintaining the minimally invasive profile of an endovascular intervention. Our vision is big, spanning the breadth of cardiovascular disease where we see compelling opportunities to reimagine therapies for millions of patients. Jupiter Endovascular is a medical technology startup located in the San Francisco Bay Area, led by a team of successful medical device entrepreneurs. We have big ambitions, with a culture built on innovation, teamwork, and speed. We have raised capital from a diversified investor base, including venture capital, private equity, corporate strategic investors, and clinician angel investors.